BRIEF-Alk Says Co Licenses Rights To Neffy

Reuters
10 Nov 2024
BRIEF-Alk Says Co Licenses Rights To Neffy

Nov 9 (Reuters) - ALK-Abello A/S ALKb.CO:

  • REG-ALK LICENSES RIGHTS TO NEFFY®, THE FIRST APPROVED ADRENALINE NASAL SPRAY FOR EMERGENCY TREATMENT OF ALLERGIC REACTIONS (ANAPHYLAXIS)

  • ALK-ABELLO A/S - ALK TO PAY USD 145 MILLION IN UPFRONT AND ADDITIONAL FUTURE MILESTONES AND SALES ROYALTIES

Source text: ID:nGNE86tMlH

Further company coverage: [ALKb.CO]

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10